Hypothalamic resistin induces hepatic insulin resistance
J. Clin. Invest. Evan D. Muse, et al. 117:1670 doi:10.1172/JCI30440 [
Go to this article.]
Figure 4The effects of increased levels of circulating plasma resistin are attenuated in animals treated with IH anti-resistin antibodies. (
A) Experimental design for hyperinsulinemic-euglycemic clamp studies. IH infusion of Con Ab or Rs Ab (0.33 μl bolus followed 0.5 μl/h infusion) was initiated at 0 minutes and continued throughout the 360-minute course of study. Resistin (30 μg total dose) was infused i.v. at a constant rate starting at 60 minutes. The remainder of the study was completed as described in Figure
1. (
B) Rates of glucose uptake during the insulin clamp studies were unaffected in all groups. (
C) The rate of endogenous GP for i.v. resistin–infused animals also receiving an IH infusion of Con Ab was greatly increased compared with controls but was attenuated in animals receiving the IH infusion of Rs Ab. (
D) Changes in the percentage suppression of endogenous GP in animals receiving i.v. resistin and IH Ab infusions. *
P < 0.05 compared with vehicle;
#P < 0.05 compared with Con Ab.
